Table of Contents
List of Tables
List of Figures
Cerus Corp Company Overview
Cerus Corp Company Snapshot
Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp – Pipeline Analysis Overview
Business Description
Cerus Corp – Key Facts
Cerus Corp – Major Products and Services
Cerus Corp Pipeline Products by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Pipeline Products Overview
INTERCEPT Blood System – Platelets
INTERCEPT Blood System – Platelets Product Overview
INTERCEPT Blood System – Platelets Clinical Trial
INTERCEPT Blood System – Red Blood Cells
INTERCEPT Blood System – Red Blood Cells Product Overview
INTERCEPT Blood System – Red Blood Cells Clinical Trial
INTERCEPT Blood System – Whole Blood
INTERCEPT Blood System – Whole Blood Product Overview
INTERCEPT Pathogen Reduced Cryoprecipitate – Poor Plasma
INTERCEPT Pathogen Reduced Cryoprecipitate – Poor Plasma Product Overview
Next Generation INTERCEPT Blood System
Next Generation INTERCEPT Blood System Product Overview
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex Product Overview
Cerus Corp – Key Competitors
Cerus Corp – Key Employees
Cerus Corp – Key Employee Biographies
Cerus Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Cerus Corp, Recent Developments
Apr 02, 2020: Cerus Corporation announces the inclusion of pathogen reduction technology in the ISBT working party recommendations for the preparation of COVID-19 convalescent plasma
Feb 18, 2020: U.S. Department of Defense awards funding for study to evaluate the use of INTERCEPT Plasma in traumatic burn resuscitation
Jan 23, 2020: Coronavirus inactivation reported in recent INTERCEPT Blood System publication in transfusion medicine
Jan 21, 2020: French Hemovigilance report highlights safety and effectiveness of INTERCEPT Platelets during first full year of 100% production and routine use
Oct 30, 2019: Cerus announces third quarter 2019 results
Oct 18, 2019: Cerus announces schedule of presentations at the 2019 AABB Annual Meeting
Sep 30, 2019: Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion
Aug 01, 2019: Cerus announces record second quarter 2019 results
Jun 24, 2019: Cerus announces presentations highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT
Jun 03, 2019: Cerus announces new corporate brand and global headquarters
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp Pipeline Products by Equipment Type
Cerus Corp Pipeline Products by Indication
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp, Key Facts
Cerus Corp, Major Products and Services
Cerus Corp Number of Pipeline Products by Development Stage
Cerus Corp Pipeline Products Summary by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Ongoing Clinical Trials Summary
INTERCEPT Blood System - Platelets - Product Status
INTERCEPT Blood System - Platelets - Product Description
INTERCEPT Blood System - Platelets - A Randomized, Multi-center, Multi-Stage, Controlled, In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
INTERCEPT Blood System - Red Blood Cells - Product Status
INTERCEPT Blood System - Red Blood Cells - Product Description
INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures
INTERCEPT Blood System - Red Blood Cells - Measurement of the Recovery and Lifespan of Red Blood Cells from Pathogen-reduced, Stored Blood Units Using Cellular Biotinylation
INTERCEPT Blood System - Red Blood Cells - Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections and Treatment Use Open-label Extension Study
INTERCEPT Blood System - Whole Blood - Product Status
INTERCEPT Blood System - Whole Blood - Product Description
INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma - Product Status
INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma - Product Description
Next Generation INTERCEPT Blood System - Product Status
Next Generation INTERCEPT Blood System - Product Description
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex - Product Status
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex - Product Description
Cerus Corp, Key Employees
Cerus Corp, Key Employee Biographies
Cerus Corp, Subsidiaries
Glossary